US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

Diamyd’s Phase III studies continue to follow plan

In her comments in today’s quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical, describes the progress in the decisive Phase III studies with the Company’s lead drug candidate Diamyd®, and comments on the Company’s strategies and efforts to build a Nordic specialty pharmaceutical company.”We have exciting times ahead of us with only one year to go before we have the results from our European Phase III study. Our hard work starts to pay off,” says Elisabeth Lindner, President and CEO of Diamyd Medical. “Besides our ongoing partnership discussions, we will primarily focus

Diamyd’s European Phase III study fully recruited

Diamyd Medical announces today that the company’s European Phase III study of the diabetes vaccine Diamyd® is now fully recruited. It is estimated that results from the study can be reported during spring 2011.320 children and adolescents between 10 and 20 years of age and recently diagnosed with type 1 diabetes have now been identified and included in the company’s European Phase III study and have received their first injection of the Diamyd® vaccine or placebo. The study is thus fully recruited. “It is clear now that we will be able to present results from the study during spring 2011

Diamyd makes investment in time-to-market

Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd®.Diamyd Medical is conducting a global Phase III program with the diabetes vaccine Diamyd®, including in total 640 children and adolescents with recent-onset type 1 diabetes. The program is composed of one study in the US and one parallel study in nine countries in Europe. The US recruitment effort will soon be launched together with

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media